Want to see CSLLY full AI Analyst Report?
CSLLY Stock Chart & Stats
$19.96
$0.34(1.70%)
At close: 4:00 PM EDT
$19.96
$0.34(1.70%)
Day’s Range― - ―
52-Week Range$16.48 - $44.07
Previous CloseN/A
Volume316.37K
Average Volume (3M)1.91K
Market Cap
$46.39B
Enterprise Value$67.76K
Total Cash (Recent Filing)$1.15B
Total Debt (Recent Filing)$12.57B
Price to Earnings (P/E)32.5
Beta0.39
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.58%
Share Statistics
EPS (TTM)0.06
Shares Outstanding1,915,648,000
10 Day Avg. Volume0
30 Day Avg. Volume1,912
Financial Highlights & Ratios
PEG Ratio7.66
Price to Book (P/B)7.93
Price to Sales (P/S)9.94
P/FCF Ratio60.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Generation & Capital ReturnsRobust operating cash flow and an enlarged buyback program provide durable financial flexibility. Reliable cash generation funds dividends, share repurchases, debt reduction and reinvestment in R&D and capacity, supporting long‑term capital allocation and balance sheet resilience.
Balance Sheet Strength And Cash ConversionModerate leverage and a strong equity base combined with high free cash flow growth underpin financial stability. This structural balance sheet profile supports funding of capital projects, M&A optionality and withstands cyclical pressures while enabling sustained investment in core operations.
Specialty Product MomentumSuccessful specialty launches and continued uptake in innovative therapies indicate durable revenue diversification. Growing adoption of HEMGENIX and ANDEMBRY reflects strong clinical positioning and commercial execution, supporting sustainable higher‑margin product mix over the medium term.
Bears Say
Large Impairments And RestructuringSubstantial noncash write‑downs and large restructuring charges create persistent reported earnings volatility and indicate reassessment of asset economics. These actions can reduce future depreciation/amortization benefits but constrain near‑term cash deployed to growth and raise execution risk on turnaround plans.
Ig Franchise Reimbursement HeadwindsStructural reimbursement changes and contract losses in core immunoglobulin products undermine a central revenue engine. Persistent payer reforms and tender dynamics can depress volumes and pricing, weakening margin sustainability and requiring sustained commercial remediation to restore prior growth.
Generics And LOE Pressure In Iron & Nephrology Tailwinds UncertaintyEntrants and patent expiries in iron therapies and impending loss of exclusivity create structural revenue risk. Generic competition and LOE reduce pricing power and may permanently lower franchise returns, requiring offset from new product introductions or cost savings to sustain margins.
CSL News
CSLLY FAQ
What was CSL Limited’s price range in the past 12 months?
CSL Limited lowest stock price was $16.48 and its highest was $44.07 in the past 12 months.
What is CSL Limited’s market cap?
CSL Limited’s market cap is $46.39B.
When is CSL Limited’s upcoming earnings report date?
CSL Limited’s upcoming earnings report date is Aug 18, 2026 which is tomorrow.
How were CSL Limited’s earnings last quarter?
CSL Limited released its earnings results on Feb 10, 2026. The company reported $0.208 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is CSL Limited overvalued?
According to Wall Street analysts CSL Limited’s price is currently Overvalued.
Does CSL Limited pay dividends?
CSL Limited pays a Semiannually dividend of $0.319 which represents an annual dividend yield of 2.58%. See more information on CSL Limited dividends here
What is CSL Limited’s EPS estimate?
CSL Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CSL Limited have?
CSL Limited has 1,915,648,000 shares outstanding.
What happened to CSL Limited’s price movement after its last earnings report?
CSL Limited reported an EPS of $0.208 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.342%.
Which hedge fund is a major shareholder of CSL Limited?
Currently, no hedge funds are holding shares in CSLLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
CSLLY Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 66.1K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.06%
12-Months-Change
Fundamentals
Return on Equity
2.58%
Trailing 12-Months
Asset Growth
-1.42%
Trailing 12-Months
Company Description
CSL Limited
CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international presence, with operations spanning major markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China, alongside other territories worldwide. Its business is primarily structured around two key divisions: CSL Behring and Seqirus. The CSL Behring segment specializes in plasma-derived and recombinant therapies, which are crucial for treating serious medical conditions including immunodeficiency, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments. This division also conducts extensive research into both plasma and non-plasma-based treatments and generates income through licensing agreements and royalties from its proprietary innovations. In contrast, the Seqirus segment is focused on manufacturing and supplying biotherapeutic products that are not derived from plasma, with a particular emphasis on the development of solutions related to influenza. CSL Limited, originally founded in 1916, has its corporate headquarters situated in Parkville, Australia.
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors